Sweet Earth Holdings Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Sweet Earth Holdings has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 12.7% per year.
Belangrijke informatie
35.5%
Groei van de winst
51.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 12.7% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | 1,891.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Sweet Earth Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 0 | 0 |
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -4 | 3 | 0 |
| 30 Sep 21 | 0 | -5 | 4 | 0 |
| 30 Jun 21 | 0 | -5 | 4 | 0 |
| 31 Mar 21 | 0 | -6 | 4 | 0 |
| 31 Dec 20 | 0 | -5 | 4 | 0 |
| 30 Sep 20 | 0 | -5 | 4 | 0 |
| 30 Jun 20 | 0 | -5 | 4 | 0 |
| 31 Mar 20 | 0 | -5 | 6 | 0 |
| 31 Dec 19 | 0 | -5 | 5 | 0 |
| 30 Sep 19 | 0 | -4 | 4 | 0 |
Kwaliteitswinsten: SE has a large one-off gain of CA$629.5K impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: SE became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SE has become profitable over the past 5 years, growing earnings by 35.5% per year.
Versnelling van de groei: SE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: SE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: SE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.